Mammalian Target of Rapamycin as a Target in Hematological Malignancies

Isam A. Abdel-Karim*, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Despite significant advances in the treatment of hematological malignancies over the previous decades, morbidity and mortality from theses disorders still remain high. New discoveries in the pathways involved in the pathophysiology led to new thinking in drug discovery. mTOR inhibitors are new and viable options for patients with these malignancies. We hope that newer clinical data will bring about new options in this field.

Original languageEnglish (US)
Pages (from-to)161-177
Number of pages17
JournalCurrent Problems in Cancer
Issue number4
StatePublished - Jul 1 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Mammalian Target of Rapamycin as a Target in Hematological Malignancies'. Together they form a unique fingerprint.

Cite this